This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	Hepatitis A virus cellular receptor 2 (HAVCR2; TIM3)	Studies in mice suggest that antibodies targeting TIM3 could help treat AML. All mice transplanted with patient-derived TIM3 ⁺ AML cells developed disease compared with none of the mice receiving TIM3 ⁻ AML cells. In mice receiving the TIM3 ⁺ AML cells, an anti-TIM3 mAb prevented disease compared with a control mAb. Next steps could include studying the role of TIM3 signaling in AML cell functions.	Patent and licensing status unavailable	Kikushige, Y. <i>et al. Cell Stem Cell</i> ; published online Dec. 3, 2010; doi:10.1016/j.stem.2010.11.014 Contact: Koichi Akashi, Kyushu University Graduate School of Medicine, Fukuoka, Japan e-mail: akashi@med.kyushu-u.ac.jp
<i>SciBX</i> 4(2); doi:10.1038/scibx.2011.37 Published online Jan. 13, 2011				